GW Pharmaceuticals (NASDAQ:GWPH) has been assigned a $192.00 target price by research analysts at Cantor Fitzgerald in a report released on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 43.14% from the stock’s previous close.
A number of other analysts also recently issued reports on GWPH. BidaskClub upgraded shares of GW Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. Zacks Investment Research downgraded shares of GW Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, December 26th. Leerink Swann reiterated a “buy” rating and issued a $153.00 price target on shares of GW Pharmaceuticals in a report on Tuesday, January 23rd. Finally, Bank of America reduced their price target on shares of GW Pharmaceuticals from $154.00 to $149.00 and set a “buy” rating on the stock in a report on Tuesday, February 6th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. GW Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $146.38.
Shares of NASDAQ GWPH opened at $134.13 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.34 and a current ratio of 11.44. The firm has a market capitalization of $3,348.51, a price-to-earnings ratio of -19.30 and a beta of 2.62. GW Pharmaceuticals has a 52-week low of $92.65 and a 52-week high of $143.37.
GW Pharmaceuticals (NASDAQ:GWPH) last announced its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported ($2.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.03) by ($0.40). The company had revenue of $7.73 million during the quarter, compared to the consensus estimate of $2.18 million. GW Pharmaceuticals had a negative net margin of 1,357.98% and a negative return on equity of 46.94%. equities analysts forecast that GW Pharmaceuticals will post -9.66 earnings per share for the current year.
Several institutional investors have recently bought and sold shares of the company. Millennium Management LLC increased its holdings in shares of GW Pharmaceuticals by 618.1% in the 4th quarter. Millennium Management LLC now owns 198,425 shares of the biopharmaceutical company’s stock worth $26,194,000 after buying an additional 170,792 shares during the last quarter. Raymond James & Associates increased its holdings in shares of GW Pharmaceuticals by 9.3% in the 4th quarter. Raymond James & Associates now owns 8,464 shares of the biopharmaceutical company’s stock worth $1,117,000 after buying an additional 718 shares during the last quarter. Ardsley Advisory Partners bought a new stake in shares of GW Pharmaceuticals in the 4th quarter worth about $1,056,000. Ellington Management Group LLC bought a new stake in shares of GW Pharmaceuticals in the 4th quarter worth about $1,373,000. Finally, Deutsche Bank AG increased its holdings in shares of GW Pharmaceuticals by 233.5% in the 4th quarter. Deutsche Bank AG now owns 228,206 shares of the biopharmaceutical company’s stock worth $30,124,000 after buying an additional 159,783 shares during the last quarter. Hedge funds and other institutional investors own 82.50% of the company’s stock.
WARNING: “GW Pharmaceuticals (GWPH) Given a $192.00 Price Target by Cantor Fitzgerald Analysts” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.thelincolnianonline.com/2018/04/18/gw-pharmaceuticals-gwph-given-a-192-00-price-target-by-cantor-fitzgerald-analysts.html.
About GW Pharmaceuticals
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.
Receive News & Ratings for GW Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.